Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Apr 15:579:119181.
doi: 10.1016/j.ijpharm.2020.119181. Epub 2020 Feb 26.

Advantages of the combined use of cyclodextrins and nanocarriers in drug delivery: A review

Affiliations
Review

Advantages of the combined use of cyclodextrins and nanocarriers in drug delivery: A review

Paola Mura. Int J Pharm. .

Abstract

Complexation with cyclodextrins (CDs) has been widely and successfully used in pharmaceutical field, mainly for enhancing solubility, stability and bioavailability of a variety of drugs. However, some important drawbacks, including rapid removal from the bloodstream after in vivo administration, or possible replacement, in biological media, of the entrapped drug moieties by other molecules with higher affinity for the CD cavity, can limit the CDs effectiveness as drug carriers. This review is focused on combined strategies simultaneously exploiting CD complexation, and loading of the complexed drug into various colloidal carriers (liposomes, niosomes, polymeric nanoparticles, lipid nanoparticles, nanoemulsions, micelles) which have been investigated as a possible means for circumventing the problems associated with both such carriers, when used separately, and join their relative benefits in a unique delivery system. Several examples of applications have been reported, to illustrate the possible advantages achievable by such a dual strategy, depending on the CD-nanocarrier combination, and mainly resulting in enhanced performance of the delivery system and improved biopharmaceutical properties and therapeutic efficacy of drugs. The major problems and/or drawbacks found in the development of such systems, as well as the (rare) case of failures in achieving the expected improvements have also been highlighted.

Keywords: Cyclodextrin complexation; Drug-in cyclodextrin-in nanocarrier; Enhanced stability; Improved drug bioavailability; Increased entrapment efficiency; carboxymethyl-β-cyclodextrin (CAS 218269-34-2); chitosan (CAS 9012-76-4); hydroxypropyl-β-cyclodextrin (CAS 128446-35-5); methyl-β-cyclodextrin (128446-36-6); phospholipid (CAS 123465-35-0); poly(lactyde-co-glycolide (PLGA) copolymers (CAS 26780-50-7); sulfobutylether-β-cyclodextrin (CAS 182410-00-0); β-cyclodextrin (CAS 7585-39-9); γ-cyclodextrin (CAS 17465-86-0).

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Similar articles

Cited by

LinkOut - more resources